These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Successful treatment of refractory juvenile generalized pustular psoriasis with secukinumab monotherapy: A case report and review of published work. Ho PH; Tsai TF J Dermatol; 2018 Nov; 45(11):1353-1356. PubMed ID: 30230584 [TBL] [Abstract][Full Text] [Related]
4. Gastrointestinal bleeding with severe mucosal involvement in a patient with generalized pustular psoriasis without IL36RN mutation. Komatsuda S; Kamata M; Chijiwa C; Namiki K; Fukaya S; Hayashi K; Fukuyasu A; Tanaka T; Ishikawa T; Ohnishi T; Abe K; Yamamoto T; Aozasa N; Sugiura K; Tada Y J Dermatol; 2019 Jan; 46(1):73-75. PubMed ID: 30474867 [TBL] [Abstract][Full Text] [Related]
5. Increased neutrophil-derived IL-17A identified in generalized pustular psoriasis. Lan Y; Wu X; Zhong X; Song P; Liu L; Liu Y; Ai X; Han C; Zhang Z Exp Dermatol; 2024 Feb; 33(2):e15026. PubMed ID: 38414093 [TBL] [Abstract][Full Text] [Related]
6. Association of IL36RN mutations with clinical features, therapeutic response to acitretin, and frequency of recurrence in patients with generalized pustular psoriasis. Zhu T; Jin H; Shu D; Li F; Wu C Eur J Dermatol; 2018 Apr; 28(2):217-224. PubMed ID: 29619998 [TBL] [Abstract][Full Text] [Related]
8. Successful therapy with anakinra in a patient with generalized pustular psoriasis carrying IL36RN mutations. Hüffmeier U; Wätzold M; Mohr J; Schön MP; Mössner R Br J Dermatol; 2014 Jan; 170(1):202-4. PubMed ID: 23909475 [No Abstract] [Full Text] [Related]
9. Mutation analysis of the IL36RN gene in Chinese patients with generalized pustular psoriasis with/without psoriasis vulgaris. Li X; Chen M; Fu X; Zhang Q; Wang Z; Yu G; Yu Y; Qin P; Wu W; Pan F; Liu H; Zhang F J Dermatol Sci; 2014 Nov; 76(2):132-8. PubMed ID: 25212972 [TBL] [Abstract][Full Text] [Related]
10. No need to change the drug class: ixekizumab- following secukinumab-therapy in psoriasis. Bokor-Billmann T; Schäkel K J Dermatolog Treat; 2019 May; 30(3):216-220. PubMed ID: 30051725 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52-week, open-label, phase 3 study (UNCOVER-J). Saeki H; Nakagawa H; Nakajo K; Ishii T; Morisaki Y; Aoki T; Cameron GS; Osuntokun OO; J Dermatol; 2017 Apr; 44(4):355-362. PubMed ID: 27726163 [TBL] [Abstract][Full Text] [Related]
12. Mutation analysis of the IL36RN gene in 14 Japanese patients with generalized pustular psoriasis. Farooq M; Nakai H; Fujimoto A; Fujikawa H; Matsuyama A; Kariya N; Aizawa A; Fujiwara H; Ito M; Shimomura Y Hum Mutat; 2013 Jan; 34(1):176-83. PubMed ID: 22903787 [TBL] [Abstract][Full Text] [Related]
13. Novel IL36RN mutation in a Japanese case of early onset generalized pustular psoriasis. Kanazawa N; Nakamura T; Mikita N; Furukawa F J Dermatol; 2013 Sep; 40(9):749-51. PubMed ID: 23834760 [TBL] [Abstract][Full Text] [Related]
15. Expression of interleukin-36 receptor antagonist in a patient with generalized pustular psoriasis harboring the p.Pro82Leu variant in the IL36RN gene. Mizukawa I; Kamata M; Shimizu T; Ito M; Watanabe A; Uchida H; Egawa S; Nagata M; Fukaya S; Hayashi K; Fukuyasu A; Tanaka T; Ishikawa T; Sugiura K; Tada Y J Dermatol; 2023 Dec; 50(12):1608-1613. PubMed ID: 37525499 [TBL] [Abstract][Full Text] [Related]
16. The majority of generalized pustular psoriasis without psoriasis vulgaris is caused by deficiency of interleukin-36 receptor antagonist. Sugiura K; Takemoto A; Yamaguchi M; Takahashi H; Shoda Y; Mitsuma T; Tsuda K; Nishida E; Togawa Y; Nakajima K; Sakakibara A; Kawachi S; Shimizu M; Ito Y; Takeichi T; Kono M; Ogawa Y; Muro Y; Ishida-Yamamoto A; Sano S; Matsue H; Morita A; Mizutani H; Iizuka H; Muto M; Akiyama M J Invest Dermatol; 2013 Nov; 133(11):2514-2521. PubMed ID: 23698098 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: A 52-week analysis from phase III open-label multicenter Japanese study. Imafuku S; Honma M; Okubo Y; Komine M; Ohtsuki M; Morita A; Seko N; Kawashima N; Ito S; Shima T; Nakagawa H J Dermatol; 2016 Sep; 43(9):1011-7. PubMed ID: 26919410 [TBL] [Abstract][Full Text] [Related]
18. The genetic background of generalized pustular psoriasis: IL36RN mutations and CARD14 gain-of-function variants. Sugiura K J Dermatol Sci; 2014 Jun; 74(3):187-92. PubMed ID: 24656634 [TBL] [Abstract][Full Text] [Related]
19. Excellent response to secukinumab in an infant with severe generalized pustular psoriasis. López-Sánchez C; Falla LM; Roé-Crespo E; Arostegui JI; Mozos A; Bernal S; Iznardo H; Baselga-Torres E J Dermatol; 2021 Jun; 48(6):907-910. PubMed ID: 33543522 [TBL] [Abstract][Full Text] [Related]
20. Acute generalized exanthematous pustulosis caused by dihydrocodeine phosphate in a patient with psoriasis vulgaris and a heterozygous IL36RN mutation. Nakai N; Sugiura K; Akiyama M; Katoh N JAMA Dermatol; 2015 Mar; 151(3):311-5. PubMed ID: 25409173 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]